RT Journal Article
SR Electronic
A1 Vinall, Phil
T1 Randomized Controlled Trials of Epratuzumab Reveal Clinically Meaningful Improvements in Patients with Moderate/Severe SLE Flares
JF MD Conference Express
YR 2008
FD SAGE Publications
VO 8
IS 5
SP 16
OP 17
DO 10.1177/155989770800800510
UL http://mdc.sagepub.com/content/8/5/16.abstract
AB This article discusses results of 2 48-week, randomized, double-blind, placebo-controlled clinical trials that evaluated the humanized anti-CD22 monoclonal antibody epratuzumab for the treatment of patients with severe BILAG A or moderate BILAG B (in =2 organ systems) systemic lupus erythematosus flares.